tesamorelin

ghrh analogue · trans-3-hexenoic-acid stabilized

FDA-approved (HIV lipodystrophy) GHRH analogue. Physiological GH stimulation without negative-feedback suppression of the axis.

vial size

for laboratory use only — not for human consumption. ships from tallinn within 24 h, EU delivery in 48 h.

research monograph

what the literature shows.

A condensed monograph drawn from preclinical and clinical literature. Cited mechanisms, specifications and the research case for tesamorelin.

01 · mechanism of action

Tesamorelin is a synthetic GHRH analogue with a trans-3-hexenoic acid modification that significantly extends its half-life vs. native GHRH. In preclinical animal studies tesamorelin stimulated pulsatile GH secretion from the pituitary physiologically — unlike exogenous GH which suppresses natural GH secretion. In HIV-associated lipodystrophy studies in primates it produced selective reduction of visceral adipose tissue (15–20 %) without affecting peripheral fat. In rat models with reduced GH secretion tesamorelin restored IGF-1, bone density and body composition to normal values. Particularly relevant for aging research: tesamorelin improved cognitive parameters in aged animal models and reduced amyloid-β accumulation in the hippocampus.

02 · product specifications

Each vial contains 10 mg tesamorelin as lyophilized powder at ≥ 99.3 % purity (HPLC). Suitable for in-vitro studies on pituitary cell biology, receptor binding assays and preclinical investigations of the growth hormone axis.

03 · research advantages

One of the few GHRH analogues with FDA approval (HIV lipodystrophy), underscoring its clinical relevance and safety characterization. Physiological GH stimulation without axis suppression makes it superior to direct GH supplementation in research settings.

datasheet

full specification.

Identity, mass, purity reference and storage profile for the current lot of tesamorelin. For laboratory use only.

catalog no.: PH-7002-T
cas: 218949-48-5
molecular weight: 5135.83 g/mol
purity (hplc): ≥ 99.3 % (hplc)
endotoxin: < 0.5 eu/mg
sequence: 44-residue stabilized ghrh(1–44) analogue
residues: 44 aa
appearance: white lyophilized powder
reconstitution: bacteriostatic water · 0.9 % nacl
stability (reconstituted): 28 d at 2–8 °c
shelf life (lyophilized): 24 m at −20 °c
storage: −20 °c, protect from light
current lot: tsm-260322
current exp.: 10 / 2027
lead time: ships in 24 h

same series · growth

from the same bench.

full catalog

PH-7001-C
phase
cjc-1295 + ipamorelin
10 mg blend
ghrh / ghrp blend · synergistic gh secretagogue
from €33.90 / 10 mgview

back to catalog